Clinical implications of the hyperdynamic syndrome in cirrhosis

European Journal of Internal Medicine

Volumn 25, Issue 9, 2014, Pages 795-802

  Licata, Anna ^a   Mazzola, Alessandra ^a   Ingrassia, Daniela ^a   Calvaruso, Vincenza ^a   Cammà, Calogero ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Ascites; CC; Cirrhosis; HPS; HRS; Hyperdynamic syndrome

Indexed keywords

ASCITES; BACTERIAL PERITONITIS; BLEEDING; CARDIOMYOPATHY; CIRRHOTIC CARDIOMYOPATHY; CLINICAL FEATURE; HEPATIC ENCEPHALOPATHY; HEPATIC HYDROTHORAX; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; HYPERDYNAMIC SYNDROME; LIVER CIRRHOSIS; PORTOPULMONARY HYPERTENSION; REVIEW; SYNDROME; VARICOSIS; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; HEART DISEASES; HEART OUTPUT; HEART RATE; HEMODYNAMICS; PATHOPHYSIOLOGY; PHYSIOLOGY; PORTAL HYPERTENSION; VASCULAR RESISTANCE;

CARDIAC OUTPUT; ESOPHAGEAL AND GASTRIC VARICES; HEART DISEASES; HEART RATE; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; SYNDROME; VASCULAR RESISTANCE;

EID: 84912084825     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.09.004     Document Type: Review

References (86)

1. Gines P, Arroyo V, Rodes J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis 1997;1:129-55.
2. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-31.
3. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-33.
4. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6(10):573-82. http://dx.doi.org/10.1038/nrgastro.2009.149.
5. García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57(2):458-61. http://dx.doi.org/10.1016/j.jhep.2012.03.007.
6. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Portal Hypertension Collaborative Group. β-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353(21):2254-61. http://dx.doi.org/10.1056/NEJMoa044456.
7. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009;50(3):604-20. http://dx.doi.org/10.1016/j.jhep.2008.12.011.
8. Hamilton G, Phing RC, Hutton RA, Dandona P, Hobbs KE. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982;2:236-42.
9. Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-5.
10. Iwakiri Y. The molecules: mechanisms of arterial vasodilation observed in the splanchinc and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;41:S288-94.
11. Geerts AM, De Vriese AS, Vanheule E, Van Vlierberghe H, Mortier S, Cheung KJ, et al. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int 2006;26:889-98.
12. Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
13. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006;290:G980-7.
14. Wiest R, Jurzik L, Herold T, Straub RH, Scholmerich J. Role of NPY for vasoregulation in the splanchnic circulation during portal hypertension. Peptides 2007;28:396-404.
15. Song D, Liu H, Sharkey KA, Lee SS. Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology 2002;35:159-66.
16. Coll M, Genesca J, Raurell I, Rodriguez-Vilarrupla A, Mejias M, Otero T, et al. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. J Hepatol 2008;49:43-51.
17. Brinch K, Moller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003;39:24-31.
18. Schrier RW. Water and sodiumretention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006;119:S47-53.
19. Kontos HA, Shapiro W, Mauck HP, Patterson Jr JL. General and regional circulatory alterations in cirrhosis of the liver. Am J Med 1964;37:526-35.
20. Maroto A, Gines P, Arroyo V, Gines A, Salo J, Claria J, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993;17:788-93.
21. Luca A, Garcia-Pagan JC, Feu F, Lopez-Talavera JC, Fernandez M, Bru C, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 1995;21:83-8.
22. Carrella M, Hunter JO, Fazio S, Del Piano C, Bartoli GC. Capillary blood flow to the skin of forearm in cirrhosis. Angiology 1992;43:969-74.
23. Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol Feb 2013;7(2):141-55. http://dx.doi.org/10.1586/egh.12.83 [Review].
24. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology 2008;47:1764-72.
25. De Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53(4):762-8.
26. Madonia S, D'Amico G, Traina M, Gatto G, Virdone R, Salamone N, et al. Prognostic indicators of successful endoscopic sclerotherapy for prevention of rebleeding from oesophageal varices in cirrhosis: a long-term cohort study. Dig Liver Dis Dec 2000;32(9):782-91 [PMID11215559].
27. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014;146(7):1680-90. http://dx.doi.org/10.1053/j.gastro.2014.03.005.
28. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8.
29. Guevara M, Cárdenas A, Uriz J, Ginès P. Prognosis in patients with cirrhosis and ascites. In: Ginès P, Arroyo V, Rodés J, Schrier RW, editors. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis and treatment. Malden: Blackwell; 2005. p. 260-70.
30. Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-53.
31. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, in hepatorenal syndrome in cirrhosis. J Hepatol Sep 2010;53(3):397-417. http://dx.doi.org/10.1016/j.jhep.2010.05.004 [Epub 2010 Jun 1].
32. Ginés P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987;92:234-41.
33. Ginès A, Fernandez-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, et al. Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
34. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8.
35. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005;54:718-25.
36. Nousbaum JB, Cadranel JF, Nahon P, Nguyen Khac E, Moreau R, Thévenot T, et al. Diagnostic accuracy of the Multistix 8 SG- reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 2007;45:1275-81.
37. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-46.
38. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.
39. Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008;23:1203-10.
40. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
41. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-90.
42. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8.
43. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9.
44. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology Nov-Dec 2003;50(54):1753-5.
45. Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol 2011;55:491-6.
46. Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, et al. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol Dec 27 2013;5(12):685-91. http://dx.doi.org/10.4254/wjh.v5.i12.685.
47. Blei AT. Monitoring cerebral blood flow: a useful clinical tool in acute liver failure? Liver Transpl 2005;11:1320-2.
48. Larsen FS. Cerebral circulation in liver failure: Ohm's law in force. Semin Liver Dis 1996;16:281-92.
49. Dillon JF, Plevris JN, Wong FC, Chan KH, Lo NT, Miller JD, et al. Middle cerebral artery blood flow velocity in patients with cirrhosis. Eur J Gastroenterol Hepatol 1995;7:1087-91.
50. Guevara M, Bru C, Gines P, Fernandez-Esparrach G, Sort P, Bataller R, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998;28:39-44.
51. Lagi A, Laffi G, Cencetti S, Barletta G, Foschi M, Vizzutti F, et al. Impaired sympathetic regulation of cerebral blood flow in patients with cirrhosis of the liver. Clin Sci (Lond) 2002;103:43-51.
52. Vaquero J, Chung C, Blei AT. Cerebral blood flow in acute liver failure: a finding in search of a mechanism. Metab Brain Dis 2004;19:177-94.
53. Butterworth Roger F. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology 2011;53(4).
54. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35(3).
55. Wijdicks EF, Nyberg SL. Propofol to control intracranial pressure in fulminant hepatic failure. Transplant Proc 2002;34:1220-2.
56. Larson AM. Diagnosis and management of acute liver failure. Curr Opin Gastroenterol 2010;26:214-21.
57. Nguyen NT, Vierling JM. Acute liver failure. Curr Opin Organ Transplant 2011;16:289-96.
58. Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome - a liver-induced lung vascular disorder. N Engl J Med 2008;358:2378-87.
59. Swanson K, Wiesner R, Krowka M. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005;41:1122-9.
60. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003;37:192-7.
61. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders [PHD]. Eur Respir J 2004;24:861-80.
62. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995;109:1283-8.
63. Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology Jan 8 2014. http://dx.doi.org/10.1053/j.gastro.2014.01.005 [pii: S0016-5085(14)00015-8].
64. Fallon MB, Mulligan DC, Gisch RG, Krowka MJ. Model for end-stage liver disease [MELD] exception for hepatopulmonary syndrome. Liver Transpl 2006;12:s105-7 [Suppl.].
65. Jyothula S, Safdar Z. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009;4:351-63.
66. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54 [Suppl.].
67. Pellicelli AM, Barbaro G, Puoti C, Guarascio P, Lusi EA, Bellis L, et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology 2010;61:802-6.
68. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-11.
69. Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transpl 2012;18(8):881-91.
70. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O' Mahony C, et al. Successful liver transplantation following medical management of portopulmonaryhypertension: a single-center series. Am J Transplant 2006;6:2177-82. http://dx.doi.org/10.1111/j.1600-6143.2006.01432.x [PMID: 16796721].
71. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258-64. http://dx.doi.org/10.1111/j.1600-6143.2006.01701.x [PMID: 17286619].
72. Malagari K, Nikita A, Alexopoulou E, Brountzos E, Papathanasiou M, Mitromaras J, et al. Cirrhosis-related intrathoracic disease. imaging features in 1038 patients. Hepatogastroenterology 2005;52:558-62.
73. Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology Apr 2014;59(4):1627-37. http://dx.doi.org/10.1002/hep.26745 [Epub 2014 Feb 25].
74. Xiol X, Castellvi JM, Guardiola J, Sese E, Castellote J, Perello A, et al. Spontaneous bacterial empyema in cirrhosis patients: a prospective study. Hepatology 1996;23:719-23.
75. Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997;25:1366-9.
76. Milanez de Campos JR, Filho LO, de Campos Werebe E, Sette Jr H, Fernandez A, Filomeno LT, et al. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000;118:13-7.
77. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol Aug 10 2010;56(7):539-49.
78. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009;85:44-54.
79. Abelmann WH, Kowalski Mc, Neely WF. The Hemodynamic Response to Exercise in patients with Laennec's Cirrhosis. J Clin Invest 1955;34(5):690-5.
80. Kim Y, Baik SK, Suk KT, Kim JW, Kim HS, Kwon SO, et al. Dobutamine stress echocardiography: a new screening method for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Hepatology 2008;48:1064F.
81. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180-8.
82. Licata A, Corrao S, Petta S, Genco C, Cardillo M, Calvaruso V, et al. NT Pro BNP plasma level and atrial volume Are linked to the severity of liver cirrhosis. PLoS One Aug 5 2013;8(8):e68364. http://dx.doi.org/10.1371/journal.pone.0068364.
83. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003;23:243-8.
84. Wong F. Cirrhotic cardiomyopathy. Hepatol Int Mar 2009;3(1):294-304.
85. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74.
86. Milani A, Zaccaria R, Bombardieri G, Gasbarrini A, Pola P. Cirrhotic cardiomyopathy. Dig Liver Dis Jun 2007;39(6):507-15.